Generic placeholder image

Current Alzheimer Research


ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Research Article

Assessment of apolipoprotein E genotype for β-amyloid status prediction

Author(s): Carmen Peña-Bautista, Lourdes Álvarez-Sánchez, Lorena García, Miguel Baquero and Consuelo Cháfer-Pericás*

Volume 18, Issue 13, 2021

Page: [1032 - 1040] Pages: 9

DOI: 10.2174/1567205019666211223141524

Price: $65


Background: Apolipoprotein E (ApoE) is the major genetic risk factor for sporadic Alzheimer's Disease (AD). Some studies showed a relationship between ApoE4 genotype and the cerebrospinal fluid (CSF) biomarkers (β-amyloid42, p-Tau, t-Tau), as well as with cognitive status. In this sense, it could be interesting to develop an approach to establish amyloid status in a minimally invasive way.

Methods: The present study assessed the ApoE genotype in different participant groups (mild cognitive impairment due to AD (MCI-AD), mild/moderate dementia due to AD, MCI not due to AD (MCI not AD), other neurological diseases, healthy participants) (n = 342).

Results: As expected, the ApoE4 allele was more prevalent in AD patients, characterized by impairment in CSF β-amyloid42 levels (Aβ +), than in the other groups (Aβ -). In this sense, ApoE4-carrier subjects showed lower CSF levels for β-amyloid42 and higher CSF levels for t-Tau and p-Tau. From this, a multivariate model to predict Aβ status was developed by means of partial least square analysis (PLS) and predictive variables (ApoE genotype, cognitive score, sex, age). This model showed suitable AUC-ROC 0.792 (95% CI, 0.744-0.840) and predictive negative value (81.6%).

Conclusion: ApoE genotype could be useful in detecting CSF β-amyloid42 impairment associated with early AD development.

Keywords: Alzheimer Disease, apolipoprotein E, diagnosis, amyloid, screening, β-amyloid.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy